Prevention of chemotherapy-induced ovarian damage: Possible roles for hormonal and non-hormonal attenuating agents

Human Reproduction Update

Volumn 20, Issue 5, 2014, Pages 759-774

  Roness, Hadassa ^a   Kalich Philosoph, Lital ^a,b   Meirow, Dror ^a,c  

^a SHEBA MEDICAL CENTER   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Female fertility; Fertility preservation; Oocyte quality; Ovarian reserve; Ovary

Indexed keywords

ABELSON KINASE; AMMONIUM TRICHLORO(DIOXYETHYLENE O,O')TELLURATE; ANGIOGENIC FACTOR; ARSENIC TRIOXIDE; CYTOTOXIC AGENT; GONADORELIN DERIVATIVE; GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; SOMATOMEDIN C; SPHINGOMYELIN; SPHINGOSINE 1 PHOSPHATE; TAMOXIFEN; THALIDOMIDE;

APOPTOSIS; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED OVARIAN DAMAGE; DNA DAMAGE; DRUG INDUCED DISEASE; DRUG MECHANISM; ENZYME INHIBITION; FERTILITY PRESERVATION; GENITAL SYSTEM FUNCTION; GONAD; HUMAN; HYPOPHYSIS GONAD SYSTEM; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OOCYTE DEVELOPMENT; OVARIAN RESERVE; OVARY DISEASE; OVARY FOLLICLE; OVARY FUNCTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW;

FEMALE FERTILITY; FERTILITY PRESERVATION; OOCYTE QUALITY; OVARIAN RESERVE; OVARY;

ANTINEOPLASTIC AGENTS; CRYOPRESERVATION; FEMALE; FERTILITY; FERTILITY PRESERVATION; HUMANS; INFERTILITY, FEMALE; NEOPLASMS; OOCYTES; OVARIAN FOLLICLE;

EID: 84906065764     PISSN: 13554786     EISSN: 14602369     Source Type: Journal    
DOI: 10.1093/humupd/dmu019     Document Type: Review

References (170)

1. Abusief ME, Missmer SA, Ginsburg ES, Weeks JC, Partridge AH. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer 2010;116:791-798.
2. Adhikari D, Liu K. Molecular mechanisms underlying the activation of mammalian primordial follicles. Endocr Rev 2009;30:438-464.
3. Ahn RW, Barrett SL, Raja MR, Jozefik JK, Spaho L, Chen H, Bally MB, Mazar AP, Avram MJ, Winter JN et al. Nano-encapsulation of arsenic trioxide enhances efficacy against murine lymphoma model while minimizing its impact on ovarian reserve in vitro and in vivo. PLoS One 2013;8:e58491.
4. Albanese R. Induction and transmission of chemically induced chromosome aberrations in female germ cells. Environ Mol Mutagen 1987;10:231-243.
5. Alcendor RR, Gao S, Zhai P, Zablocki D, Holle E, Yu X, Tian B,Wagner T, Vatner SF, Sadoshima J. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ Res 2007;100:1512-1521.
6. Anderson RA, Themmen AP, Al-Qahtani A, GroomeNP, Cameron DA. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod 2006;21:2583-2592.
7. Anderson RA, Wallace WH. Antimullerian hormone, the assessment of the ovarian reserve, and the reproductive outcome of the young patient with cancer. Fertil Steril 2013;99:1469-1475.
8. Armstrong DG,Webb R. Ovarian follicular dominance: the role of intraovarian growth factors and novel proteins. Rev Reprod 1997;2:139-146.
9. Arnon J, Meirow D, Lewis-Roness H, Ornoy A. Genetic and teratogenic effects of cancer treatments on gametes and embryos. HumReprod Update 2001;7:394-403.
10. Ataya K, Rao LV, Lawrence E, Kimmel R. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod 1995;52:365-372.
11. Badawy A, Elnashar A, El-Ashry M, Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 2009;91:694-697.
12. Baeza I, Fdez-Tresguerres J, Ariznavarreta C, De la Fuente M. Effects of growth hormone, melatonin, oestrogens and phytoestrogens on the oxidized glutathione (GSSG)/reduced glutathione (GSH) ratio and lipid peroxidation in aged ovariectomized rats. Biogerontology 2010;11:687-701.
13. Baird DT, Campbell B, de Souza C, Telfer E. Long-term ovarian function in sheep after ovariectomy and autotransplantation of cryopreserved cortical strips. Eur J Obstet Gynecol Reprod Biol 2004;113 Suppl 1:S55-59.
14. Bar-Joseph H, Ben-Aharon I, Rizel S, Stemmer SM, Tzabari M, Shalgi R. Doxorubicin-induced apoptosis in germinal vesicle (GV) oocytes. Reprod Toxicol 2010;30:566-572.
15. Bar-Joseph H, Ben-Aharon I, Tzabari M, Tsarfaty G, Stemmer SM, Shalgi R. In vivo Bioimaging as a Novel Strategy to Detect Doxorubicin-Induced Damage to Gonadal Blood Vessels. PLoS One 2011;6:e23492.
16. Bath LE, Wallace WH, Shaw MP, Fitzpatrick C, Anderson RA. Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Mullerian hormone, inhibin B and ovarian ultrasound. Hum Reprod 2003; 18:2368-2374.
17. Becker K, Schoneich J. Expression of genetic damage induced by alkylating agents in germ cells of female mice. Mutat Res 1982;92:447-464.
18. Behringer K, Breuer K, Reineke T, May M, Nogova L, Klimm B, Schmitz T, Wildt L, Diehl V, Engert A. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2005;23:7555-7564.
19. Behringer K, Mueller H, Goergen H, Thielen I, Eibl AD, Stumpf V, Wessels C, Wiehlputz M, Rosenbrock J, Halbsguth T et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol 2013;31:231-239.
20. Ben-Aharon I, Gafter-Gvili A, Leibovici L, Stemmer SM. Pharmacological interventions for fertility preservation during chemotherapy: a systematic review and meta-analysis. Breast Cancer Res Treat 2010;122:803-811.
21. Bergeron L, Perez GI, Macdonald G, Shi L, Sun Y, Jurisicova A, Varmuza S, Latham KE, Flaws JA, Salter JC et al. Defects in regulation of apoptosis in caspase-2-deficient mice. Genes Dev 1998;12:1304-1314.
22. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996; 14:1718-1729.
23. Blommaert FA, Michael C, van Dijk-Knijnenburg HC, Schornagel JH, den Engelse L, Fichtinger-Schepman AM. The formation and persistence of carboplatin-DNA adducts in rats. Cancer Chemother Pharmacol 1996;38:273-280.
24. Blommaert FA, van Dijk-Knijnenburg HC, Dijt FJ, den Engelse L, Baan RA, Berends F, Fichtinger-Schepman AM. Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells. Biochemistry 1995;34:8474-8480.
25. Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist 2007;12:1044-1054.
26. Blumenfeld Z. Chemotherapy and fertility. Best Pract Res Clin Obstet Gynaecol 2012; 26:379-390.
27. Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 2004;22:2835-2841.
28. BrownJR,Modell E, Obasaju M, King YK. Natural cycle in-vitro fertilization with embryo cryopreservation prior to chemotherapy for carcinoma of the breast. Hum Reprod 1996;11:197-199.
29. Burstein HJ, Winer EP. Primary care for survivors of breast cancer. N Engl J Med 2000; 343:1086-1094.
30. Brusamolino E, Baio A, Orlandi E, Arcaini L, Passamonti F, Griva V, Casagrande W, Pascutto C, Franchini P, Lazzarino M. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up. Clin Cancer Res 2006;12:6487-6493.
31. Carmely A, MeirowD, Peretz A, Albeck M, Bartoov B, Sredni B. Protective effect of the immunomodulator AS101 against cyclophosphamide-induced testicular damage in mice. Hum Reprod 2009;24:1322-1329.
32. Carroll J, Marangos P. The DNA damage response in mammalian oocytes. Front Genet 2013;4:117.
33. Chen H, Li J, Cui T, Hu L. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev 2011:CD008018.
34. Chung K, Donnez J, Ginsburg E, Meirow D. Emergency IVF versus ovarian tissue cryopreservation: decision making in fertility preservation for female cancer patients. Fertil Steril 2013;99:1534-1542.
35. Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, Kessler B, Howitz KT, Gorospe M, de Cabo R, Sinclair DA. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 2004;305:390-392.
36. Dalberg K, Eriksson J, Holmberg L. Birth outcome in women with previously treated breast cancer-a population-based cohort study from Sweden. PLoS Med 2006; 3:e336.
37. Dann EJ, Epelbaum R, Avivi I, Ben Shahar M, Haim N, Rowe JM, Blumenfeld Z. Fertility and ovarian function are preserved in women treated with an intensified regimen of cyclophosphamide, adriamycin, vincristine and prednisone (Mega-CHOP) for non-Hodgkin lymphoma. Hum Reprod 2005;20:2247-2249.
38. Davis AL, Klitus M, Mintzer DM. Chemotherapy-induced amenorrhea from adjuvant breast cancer treatment: the effect of the addition of taxanes. Clin Breast Cancer 2005;6:421-424.
39. Decanter C, Morschhauser F, Pigny P, Lefebvre C, Gallo C, Dewailly D. Anti-Mullerian hormone follow-up in young women treated by chemotherapy for lymphoma: preliminary results. Reprod Biomed Online 2010;20:280-285.
40. Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, Gori S, Giordano M, Garrone O, Pronzato P, Bighin C et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 2011;306:269-276.
41. Del Mastro L, Ceppi M, Poggio F, Bighin C, Peccatori F, Demeestere I, Levaggi A, Giraudi S, Lambertini M, D'Alonzo A et al. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: Systematic review and meta-analysis of randomized trials. Cancer Treat Rev 2014;40:675-683.
42. Demeestere I, Brice P, Peccatori FA, Kentos A, Gaillard I, Zachee P, Casasnovas RO, Van Den Neste E, Dechene J, De Maertelaer V et al. Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial. J Clin Oncol 2013;31:903-909.
43. Depalo R, Nappi L, Loverro G, Bettocchi S, Caruso ML, Valentini AM, Selvaggi L. Evidence of apoptosis in human primordial and primary follicles. Hum Reprod 2003;18:2678-2682.
44. Dharia SP, Steinkampf MP, Cater C. Thalidomide-induced amenorrhea: case report literature review. Fertil Steril 2004;82:460-462.
45. Di Giacomo M, Barchi M, Baudat F, Edelmann W, Keeney S, Jasin M. Distinct DNA-damage-dependent and -independent responses drive the loss of oocytes in recombination-defective mouse mutants. Proc Natl Acad Sci U S A 2005; 102:737-742.
46. Doll DC, Ringenberg QS, Yarbro JW. Vascular toxicity associated with antineoplastic agents. J Clin Oncol 1986;4:1405-1417.
47. Dubey RK, Tyurina YY, Tyurin VA, Gillespie DG, Branch RA, Jackson EK, Kagan VE. Estrogen and tamoxifen metabolites protect smooth muscle cell membrane phospholipids against peroxidation and inhibit cell growth. Circ Res 1999;84: 229-239.
48. Elgindy EA, El-Haieg DO, Khorshid OM, Ismail EI, Abdelgawad M, Sallam HN, Abou-Setta AM. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. Obstet Gynecol 2013;121:78-86.
49. Familiari G, Caggiati A, Nottola SA, Ermini M, Di Benedetto MR, Motta PM. Ultrastructure of human ovarian primordial follicles after combination chemotherapy for Hodgkin's disease. Hum Reprod 1993;8:2080-2087.
50. Fornier MN, Modi S, Panageas KS, Norton L, Hudis C. Incidence of chemotherapy induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer 2005;104:1575-1579.
51. Gannon AM, Stampfli MR, Foster WG. Cigarette Smoke Exposure Leads to Follicle Loss via an Alternative Ovarian Cell Death Pathway in a Mouse Model. Toxicol Sci 2012;125:274-284.
52. Ganz PA, Land SR, Geyer CE Jr., Cecchini RS, Costantino JP, Pajon ER, Fehrenbacher L, Atkins JN, Polikoff JA, Vogel VG et al. Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol 2011;29:1110-1116.
53. Gavish Z, Peer G., Meirow D. Ovarian follicular reserve following xenotransplantation of bovine ovarian cortical tissue. Acomparison between thin and thick grafts Annual meeting of the Israeli fertility research association (AYALA). 2012, Tel Aviv, Israel.
54. Gerber B, von Minckwitz G, Stehle H, Reimer T, Felberbaum R, Maass N, Fischer D, Sommer HL, Conrad B, Ortmann O et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol 2011;29:2334-2341.
55. Gonfloni S, DiTella L, Caldarola S, Cannata SM, Klinger FG, Di Bartolomeo C, Mattei M, Candi E, De Felici M, Melino Get al. Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death. Nat Med 2009;15:1179-1185.
56. Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999;17:2365-2370.
57. Gougeon A. Dynamics of follicular growth in the human: a model from preliminary results. Hum Reprod 1986;1:81-87.
58. Gracia CR, SammelMD,Freeman E, Prewitt M, Carlson C, Ray A, Vance A, Ginsberg JP. Impact of cancer therapies on ovarian reserve. Fertil Steril 2012;97:134-140 e131.
59. Green DM, Sklar CA, Boice JD Jr., Mulvihill JJ, Whitton JA, Stovall M, Yasui Y. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol 2009;27:2374-2381.
60. Green DM, Whitton JA, Stovall M, Mertens AC, Donaldson SS, Ruymann FB, Pendergrass TW, Robison LL. Pregnancy outcome of female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Am J Obstet Gynecol 2002;187:1070-1080.
61. Han HS, Ro J, Lee KS, Nam BH, Seo JA, Lee DH, Lee H, Lee ES, Kang HS, Kim SW. Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer. Breast Cancer Res Treat 2009;115:335-342.
62. Hancke K, Strauch O, Kissel C, Gobel H, Schafer W, Denschlag D. Sphingosine 1-phosphate protects ovaries from chemotherapy-induced damage in vivo. Fertil Steril 2007;87:172-177.
63. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene 2005;24:2899-2908.
64. Hayun M, Naor Y,Weil M, Albeck M, Peled A, Don J, Haran-Ghera N, Sredni B. The immunomodulator AS101 induces growth arrest and apoptosis in multiple myeloma: association with the Akt/survivin pathway. Biochem Pharmacol 2006; 72:1423-1431.
65. Herrmann G, Spanel-Borowski K. A sparsely vascularised zone in the cortex of the bovine ovary. Anat Histol Embryol 1998;27:143-146.
66. Higdon RE, Marchetti F, Mailhes JB, Phillips GL. The effects of cisplatin on murine metaphase II oocytes. Gynecol Oncol 1992;47:348-352.
67. Higgins MJ, Liedke PE, Goss PE. Extended adjuvant endocrine therapy in hormone dependent breast cancer: the paradigm of the NCIC-CTG MA.17/BIG 1-97 trial. Crit Rev Oncol Hematol 2013;86:23-32.
68. Himelstein-Braw R, Peters H, Faber M. Morphological study of the ovaries of leukaemic children. Br J Cancer 1978;38:82-87.
69. Hortobagyi GN, Buzdar AU, Marcus CE, Smith TL. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute. NCI Monogr 1986:105-109.
70. Hsueh AJ, McGee EA, Hayashi M, Hsu SY. Hormonal regulation of early follicle development in the rat ovary. Mol Cell Endocrinol 2000;163:95-100.
71. Indenbaum V, Bin H, Makarovsky D, Weil M, Shulman LM, Albeck M, Sredni B, Mendelson E. In vitro and in vivo activity of AS101 against West Nile virus (WNV). Virus Res 2012;166:68-76.
72. Jeong J, Juhn K, Lee H, Kim SH, Min BH, Lee KM, Cho MH, Park GH, Lee KH. SIRT1 promotes DNA repair activity and deacetylation of Ku70. Exp Mol Med 2007; 39:8-13.
73. Jurisicova A, Lee HJ, D'Estaing SG, Tilly J, Perez GI. Molecular requirements for doxorubicin-mediated death in murine oocytes. Cell Death Differ 2006; 13:1466-1474.
74. Kalechman Y, Albeck M, Oron M, Sobelman D, Gurwith M, Horwith G, Kirsch T, Maida B, Sehgal SN, Sredni B. Protective and restorative role of AS101 in combination with chemotherapy. Cancer Res 1991;51:1499-1503.
75. Kalechman Y, Shani A, Sotnik-Barkai I, Albeck M, Sredni B. The protective role of ammonium trichloro(dioxoethylene-O,O')tellurate in combination with several cytotoxic drugs acting by different mechanisms of action. Cancer Res 1993; 53:5962-5969.
76. Kalechman Y, Sotnik-Barkai I, Albeck M, Sredni B. Protection of bone marrow stromal cells from the toxic effects of cyclophosphamide in vivo and of ASTA-Z 7557 and etoposide in vitro by ammonium trichloro(dioxyethylene-O-O')tellurate (AS101). Cancer Res 1993;53:1838-1844.
77. Kalich-Philosoph LRH, Carmely A, Fishel M, Ligumsky H, Paglin S, Wolf I, Kanety H, Sredni B, Meirow D. Cyclophosphamide triggers follicle activation causing ovarian reserve 'burn out'; AS101 prevents follicle loss and preserves fertility. Science Translational Medicine 2013;15:185.
78. Katoh MA, Cain KT, Hughes LA, Foxworth LB, Bishop JB, Generoso WM. Female-specific dominant lethal effects in mice. Mutat Res 1990;230: 205-217.
79. Kawamura K, Cheng Y, Suzuki N, Deguchi M, Sato Y, Takae S, Ho CH, Kawamura N, Tamura M, Hashimoto S et al. Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatment. Proc Natl Acad Sci U S A 2013; 110:17474-17479.
80. Kaya H, Desdicioglu R, Sezik M, Ulukaya E, Ozkaya O, Yilmaztepe A, Demirci M. Does sphingosine-1-phosphate have a protective effect on cyclophosphamideirradiation- induced ovarian damage in the rat model? Fertil Steril 2008;89:732-735.
81. Kerr JB, Hutt KJ, Michalak EM, Cook M, Vandenberg CJ, Liew SH, Bouillet P, Mills A, Scott CL, Findlay JK et al. DNA Damage-Induced Primordial Follicle Oocyte Apoptosis and Loss of Fertility Require TAp63-Mediated Induction of Puma and Noxa. Mol Cell 2012;48:343-352.
82. Kharbanda S, Pandey P, Morris PL, Whang Y, Xu Y, Sawant S, Zhu LJ, Kumar N, Yuan ZM, Weichselbaum R et al. Functional role for the c-Abl tyrosine kinase in meiosis I. Oncogene 1998;16:1773-1777.
83. Kharbanda S, Yuan ZM,Weichselbaum R, Kufe D. Determination of cell fate by c-Abl activation in the response to DNA damage. Oncogene 1998;17:3309-3318.
84. Kim SS, Lee JR, Jee BC, Suh CS, Kim SH, Ting A, Petroff B. Use of hormonal protection for chemotherapy-induced gonadotoxicity. Clin Obstet Gynecol 2010; 53:740-752.
85. Kishk EA,Mohammed AliMH.Effect of a gonadotropin-releasing hormone analogue on cyclophosphamide-induced ovarian toxicity in adult mice. Arch Gynecol Obstet 2013; 287:1023-1029.
86. Kreuser ED, Felsenberg D, Behles C, Seibt-Jung H, Mielcarek M, Diehl V, Dahmen E, Thiel E. Long-term gonadal dysfunction and its impact on bone mineralization in patients following COPP/ABVD chemotherapy for Hodgkin's disease. Ann Oncol 1992;3 Suppl 4:105-110.
87. Kujjo LL, Chang EA, Pereira RJ, Dhar S, Marrero-Rosado B, Sengupta S, Wang H, Cibelli JB, Perez GI. Chemotherapy-induced late transgenerational effects in mice. PLoS One 2011;6:e17877.
88. Kujjo LL, Laine T, Pereira RJ, Kagawa W, Kurumizaka H, Yokoyama S, Perez GI.Enhancing survival of mouse oocytes following chemotherapy or aging by targeting Bax and Rad51. PLoS One 2010;5:e9204.
89. Kujjo LL, Ronningen R, Ross P, Pereira RJ, Rodriguez R, Beyhan Z, Goissis MD, Baumann T, Kagawa W, Camsari C et al. RAD51 plays a crucial role in halting cell death program induced by ionizing radiation in bovine oocytes. Biol Reprod 2012; 86:76.
90. Kurita T, Cunha GR, Robboy SJ, Mills AA, Medina RT. Differential expression of p63 isoforms in female reproductive organs. Mech Dev 2005;122:1043-1055.
91. Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, Beck LN, Brennan LV, Oktay K. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006;24:2917-2931.
92. Li J, Kawamura K, Cheng Y, Liu S, Klein C, Duan EK, Hsueh AJ. Activation of dormant ovarian follicles to generate mature eggs. Proc Natl Acad Sci U S A 2010; 107:10280-10284.
93. Li X, Kang X, Deng Q, Cai J,Wang Z. Combination of aGnRH agonist with an antagonist prevents flare-up effects and protects primordial ovarian follicles in the rat ovary from cisplatin-induced toxicity: a controlled experimental animal study. Reprod Biol Endocrinol 2013;11:16.
94. Livera G, Petre-Lazar B, Guerquin MJ, Trautmann E, Coffigny H, Habert R. p63 null mutation protects mouse oocytes from radio-induced apoptosis. Reproduction 2008;135:3-12.
95. Mahran YF, El-Demerdash E, Nada AS, Ali AA, Abdel-Naim AB. Insights into the protective mechanisms of tamoxifen in radiotherapy-induced ovarian follicular loss: impact on insulin-like growth factor 1. Endocrinology 2013; 154:3888-3899.
96. Maiani E, Di Bartolomeo C, Klinger FG, Cannata SM, Bernardini S, Chateauvieux S, Mack F, Mattei M, De Felici M, Diederich M et al. Reply to: Cisplatin-induced primordial follicle oocyte killing and loss of fertility are not prevented by imatinib. Nat Med 2012;18:1172-1174.
97. Mailhes JB. Important biological variables that can influence the degree of chemical-induced aneuploidy in mammalian oocyte and zygotes. Mutat Res 1995; 339:155-176.
98. Mailhes JB, Carabatsos MJ, Young D, London SN, Bell M, Albertini DF. Taxol-induced meiotic maturation delay, spindle defects, and aneuploidy in mouse oocytes and zygotes. Mutat Res 1999;423:79-90.
99. Makarovsky D, Kalechman Y, Sonino T, Freidkin I, Teitz S, Albeck M, Weil M, Geffen-Aricha R, Yadid G, Sredni B. Tellurium compound AS101 induces PC12 differentiation and rescues the neurons from apoptotic death. Ann N Y Acad Sci 2003;1010:659-666.
100. Maneschi F, Benedetti-Panici P, Scambia G, Salerno MG, D'Agostino G, Mancuso S. Menstrual and hormone patterns in women treated with high-dose cisplatin and bleomycin. Gynecol Oncol 1994;54:345-348.
101. MaoZ, Hine C, Tian X, Van Meter M,Au M, Vaidya A, Seluanov A, GorbunovaV. SIRT6 promotes DNA repair under stress by activating PARP1. Science 2011;332: 1443-1446.
102. Marcello MF, Nuciforo G, Romeo R, Di Dino G, Russo I, Russo A, Palumbo G, Schiliro G. Structural and ultrastructural study of the ovary in childhood leukemia after successful treatment. Cancer 1990;66:2099-2104.
103. Matsushita N, Takami Y, Kimura M, Tachiiri S, Ishiai M, Nakayama T, TakataM. Role of NAD-dependent deacetylases SIRT1 and SIRT2 in radiation and cisplatin-induced cell death in vertebrate cells. Genes Cells 2005;10:321-332.
104. McGee EA, Hsueh AJ. Initial and cyclic recruitment of ovarian follicles. Endocr Rev 2000; 21:200-214.
105. Meirow D. Reproduction post-chemotherapy in young cancer patients. Mol Cell Endocrinol 2000;169:123-131.
106. Meirow D, Assad G, Dor J, Rabinovici J. The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice. Hum Reprod 2004;19:1294-1299.
107. Meirow D, Biederman H, Anderson RA,Wallace WH. Toxicity of chemotherapy and radiation on female reproduction. Clin Obstet Gynecol 2010;53:727-739.
108. Meirow D, Dor J, Kaufman B, Shrim A, Rabinovici J, Schiff E, Raanani H, Levron J, Fridman E. Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury. Hum Reprod 2007; 22:1626-1633.
109. Meirow D, Epstein M, Lewis H, Nugent D, Gosden RG. Administration of cyclophosphamide at different stages of follicular maturation in mice: effects on reproductive performance and fetal malformations.Hum Reprod 2001;16:632-637.
110. Meirow D, Lewis H, Nugent D, Epstein M. Subclinical depletion of primordial follicular reserve in mice treated with cyclophosphamide: clinical importance and proposed accurate investigative tool. Hum Reprod 1999;14:1903-1907.
111. Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update 2001;7:535-543.
112. Meirow D, Schiff E. Appraisal of chemotherapy effects on reproductive outcome according to animal studies and clinical data. J Natl Cancer Inst Monogr 2005:21-25.
113. Meirow D,Wallace WH. Preservation of fertility in patients with cancer. N Engl J Med 2009;360:2682; author reply 2682-2683.
114. Mitchison TJ. The proliferation rate paradox in antimitotic chemotherapy. Mol Biol Cell 2012;23:1-6.
115. Mol F, MolBW, AnkumWM,van der Veen F, Hajenius PJ. Current evidence on surgery, systemic methotrexate and expectant management in the treatment of tubal ectopic pregnancy: a systematic review and meta-analysis. Hum Reprod Update 2008; 14:309-319.
116. Morita Y, Perez GI, Maravei DV, Tilly KI, Tilly JL. Targeted expression of Bcl-2 in mouse oocytes inhibits ovarian follicle atresia and prevents spontaneous and chemotherapy-induced oocyte apoptosis in vitro. Mol Endocrinol 1999;13:841-850.
117. Morita Y, Perez GI, Paris F, Miranda SR, Ehleiter D, Haimovitz-Friedman A, Fuks Z, Xie Z, Reed JC, Schuchman EH et al. Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy. Nat Med 2000;6:1109-1114.
118. Motta PM, Heyn R, Makabe S. Three-dimensional microanatomical dynamics of the ovary in postreproductive aged women. Fertil Steril 2002;78:360-370.
119. Mueller BA, Chow EJ, Kamineni A, Daling JR, Fraser A, Wiggins CL, Mineau GP, Hamre MR, Severson RK, Drews-Botsch C. Pregnancy outcomes in female childhood and adolescent cancer survivors: a linked cancer-birth registry analysis. Arch Pediatr Adolesc Med 2009;163:879-886.
120. Munster PN, Moore AP, Ismail-Khan R, Cox CE, Lacevic M, Gross-King M, Xu P, Carter WB, Minton SE. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol 2012;30:533-538.
121. Nathan L, Chaudhuri G. Antioxidant and prooxidant actions of estrogens: potential physiological and clinical implications. Semin Reprod Endocrinol 1998; 16:309-314.
122. Nicosia SV, Matus-Ridley M, Meadows AT. Gonadal effects of cancer therapy in girls. Cancer 1985;55:2364-2372.
123. Nozaki Y, Furubo E, Matsuno T, Fukui R, Kizawa K, Kozaki T, Sanzen T. Collaborative work on evaluation of ovarian toxicity. 6) Two- or four-week repeated-dose studies and fertility study of cisplatin in female rats. J Toxicol Sci 2009;34 Suppl 1:SP73-81.
124. Ochalski ME, Shuttleworth JJ, Chu T, Orwig KE. Thalidomide treatment attenuates chemotherapy-induced gonadal toxicity. Fertil Steril 2011;95:819-822.
125. Oktem O, Oktay K. A novel ovarian xenografting model to characterize the impact of chemotherapy agents on human primordial follicle reserve. Cancer Res 2007; 67:10159-10162.
126. OktemO, Oktay K. Quantitative assessment of the impact of chemotherapyon ovarian follicle reserve and stromal function. Cancer 2007;110:2222-2229.
127. Oriol B, Barrio A, Pacheco A, Serna J, Zuzuarregui JL, Garcia-Velasco JA. Systemic methotrexate to treat ectopic pregnancy does not affect ovarian reserve. Fertil Steril 2008;90:1579-1582.
128. Paris F, Perez GI, Fuks Z, Haimovitz-Friedman A, Nguyen H, Bose M, Ilagan A, Hunt PA, Morgan WF, Tilly JL et al. Sphingosine 1-phosphate preserves fertility in irradiated female mice without propagating genomic damage in offspring. Nat Med 2002; 8:901-902.
129. Partridge AH, Ruddy KJ, Gelber S, Schapira L, Abusief M, Meyer M, Ginsburg E. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil Steril 2010;94:638-644.
130. Perez GI, Acton BM, Jurisicova A, Perkins GA, White A, Brown J, Trbovich AM, Kim MR, Fissore R, Xu J et al. Genetic variance modifies apoptosis susceptibility in mature oocytes via alterations in DNA repair capacity and mitochondrial ultrastructure. Cell Death Differ 2007;14:524-533.
131. Perez GI, Knudson CM, Leykin L, Korsmeyer SJ, Tilly JL. Apoptosis-associated signaling pathways are required for chemotherapy-mediated female germ cell destruction. Nat Med 1997;3:1228-1232.
132. Perez GI, Tao XJ, Tilly JL. Fragmentation and death (a.k.a. apoptosis) of ovulated oocytes. Mol Hum Reprod 1999;5:414-420.
133. Petrek JA, Naughton MJ, Case LD, Paskett ED, Naftalis EZ, Singletary SE, Sukumvanich P. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 2006; 24:1045-1051.
134. Pfeifer S, Goldberg J, McClure R, Lobo R, Thomas M, Widra E, Licht M, Collins J, Cedars M, Racowsky C et al. Mature oocyte cryopreservation: a guideline. Fertil Steril 2013;99:37-43.
135. Picton HM, Harris SE, MuruviW, Chambers EL. The in vitro growth and maturation of follicles. Reproduction 2008;136:703-715.
136. Rabinovici J, Jaffe RB. Development and regulation of growth and differentiated function in human and subhuman primate fetal gonads. Endocr Rev 1990; 11:532-557.
137. Reeves G. Specific stromain the cortex and medulla of the ovary. Cell types and vascular supply in relation to follicular apparatus and ovulation. Obstet Gynecol 1971; 37:832-844.
138. RehA,Oktem O, Oktay K. Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers. Fertil Steril 2008;90:1635-1639.
139. Roness H. Cyclophosphamide triggers follicle activation causing ovarian reserve 'burn out'; AS101 preserves fertility ESHRE. 2013, London.
140. Roti Roti EC, Leisman SK, Abbott DH, Salih SM. Acute doxorubicin insult in the mouse ovary is cell- and follicle-type dependent. PLoS One 2012;7:e42293.
141. Russo A, Pacchierotti F. Meiotic arrest and aneuploidy induced by vinblastine in mouse oocytes. Mutat Res 1988;202:215-221.
142. Sato M, Shiozawa K, Uesugi T, Hiromatsu R, Fukuda M, Kitaura K, Minami T, Matsumoto S. Collaborative work on evaluation of ovarian toxicity. 7) Effects of 2- or 4- week repeated dose studies and fertility study of cyclophosphamide in female rats. J Toxicol Sci 2009;34 Suppl 1:SP83-89.
143. Skaznik-Wikiel ME, McGuire MM, Sukhwani M, Donohue J, Chu T, Krivak TC, Rajkovic A, Orwig KE. Granulocyte colony-stimulating factor with or without stem cell factor extends time to premature ovarian insufficiency in female mice treated with alkylating chemotherapy. Fertil Steril 2013;99:2045-2054 e2043.
144. Sklar CA, Mertens AC, Mitby P, Whitton J, Stovall M, Kasper C, Mulder J, Green D, Nicholson HS, Yasui Y et al. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst 2006; 98:890-896.
145. SobinoffAP, Nixon B,RomanSD, McLaughlin EA. Staying alive: PI3K pathway promotes primordial follicle activation and survival in response to 3-MC induced ovotoxicity. Toxicol Sci 2012;128:258-271.
146. Soleimani R, Heytens E, Oktay K. Enhancement of neoangiogenesis and follicle survival by sphingosine-1-phosphate in human ovarian tissue xenotransplants. PLoS One 2011;6:e19475.
147. Sredni B. Immunomodulating tellurium compounds as anti-cancer agents. Seminars in Cancer Biology 2012;22:60-69.
148. Sredni B, Albeck M, Kazimirsky G, Shalit F. The immunomodulator AS101 administered orally as a chemoprotective and radioprotective agent. Int J Immunopharmacol 1992; 14:613-619.
149. Suh EK, Yang A, Kettenbach A, Bamberger C, Michaelis AH, Zhu Z, Elvin JA, Bronson RT, Crum CP, McKeon F. p63 protects the female germ line during meiotic arrest. Nature 2006;444:624-628.
150. Sukumvanich P, Case LD, Van Zee K, Singletary SE, Paskett ED, Petrek JA, Naftalis E, Naughton MJ. Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: a prospective study. Cancer 2010;116:3102-3111.
151. Sverrisdottir A, Nystedt M, Johansson H, Fornander T. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat 2009;117:561-567.
152. Svirsky R, Rozovski U, Vaknin Z, Pansky M, Schneider D, Halperin R. The safety of conception occurring shortly after methotrexate treatment of an ectopic pregnancy. Reprod Toxicol 2009;27:85-87.
153. Takai Y, Matikainen T, Jurisicova A, Kim MR, Trbovich AM, Fujita E, Nakagawa T, Lemmers B, Flavell RA, Hakem R et al. Caspase-12 compensates for lack of caspase-2 and caspase-3 in female germ cells. Apoptosis 2007;12:791-800.
154. Tateno H, Kamiguchi Y, Shimada M, Sugawara S, Mikamo K. Induction of aneuploidy in Chinese hamster oocytes following in vivo treatments with trimethoxybenzoic compounds and their analogues. Mutat Res 1995;327:237-246.
155. Telfer EE, McLaughlin M, Ding C, Thong KJ. A two-step serum-free culture system supports development of human oocytes from primordial follicles in the presence of activin. Hum Reprod 2008;23:1151-1158.
156. Teo SK. Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS J 2005;7:E14-19.
157. Tilly JL. Molecular and genetic basis of normal and toxicant-induced apoptosis in female germ cells. Toxicol Lett 1998;102-103:497-501.
158. Ting AY, Petroff BK. Tamoxifen decreases ovarian follicular loss from experimental toxicant DMBA and chemotherapy agents cyclophosphamide and doxorubicin in the rat. J Assist Reprod Genet 2010;27:591-597.
159. Utsunomiya T, Tanaka T, Utsunomiya H, Umesaki N. A novel molecular mechanism for anticancer drug-induced ovarian failure: Irinotecan HCl, an anticancer topoisomerase I inhibitor, induces specific FasL expression in granulosa cells of large ovarian follicles to enhance follicular apoptosis. Int J Oncol 2008;32:991-1000.
160. Waxman J. Chemotherapy and the adult gonad: a review. J R Soc Med 1983; 76:144-148.
161. Winther JF, Boice JD Jr., Mulvihill JJ, Stovall M, Frederiksen K, Tawn EJ, Olsen JH. Chromosomal abnormalities among offspring of childhood-cancer survivors in Denmark: a population-based study. Am J Hum Genet 2004;74:1282-1285.
162. Woodruff TK. Preserving fertility during cancer treatment. Nat Med 2009; 15:1124-1125.
163. Wu Y, Kantake N, Sugiyama T, Kowalczykowski SC. Rad51 protein controls Rad 52-mediated DNA annealing. J Biol Chem 2008;283:14883-14892.
164. Xiang Y, Xu J, Li L, Lin X, Chen X, Zhang X, Fu Y, Luo L. Calorie restriction increases primordial follicle reserve in mature female chemotherapy-treated rats. Gene 2012; 493:77-82.
165. Yang B, Shi W, Yang J, Liu H, Zhao H, Li X, Jiao S. Concurrent treatment with gonadotropin-releasing hormone agonists for chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a meta-analysis of randomized controlled trials. Breast 2013;22:150-157.
166. Yoshida K, Miki Y. Enabling death by the Abl tyrosine kinase: mechanisms for nuclear shuttling of c-Abl in response to DNA damage. Cell Cycle 2005;4:777-779.
167. Yucebilgin MS, Terek MC, Ozsaran A, Akercan F, Zekioglu O, Isik E, Erhan Y. Effect of chemotherapy on primordial follicular reserve of rat: an animal model of premature ovarian failure and infertility. Aust N Z J Obstet Gynaecol 2004; 44:6-9.
168. Zelinski MB, Murphy MK, Lawson MS, Jurisicova A, Pau KY, Toscano NP, Jacob DS, Fanton JK, Casper RF, Dertinger SD et al. In vivo delivery of FTY720 prevents radiation-induced ovarian failure and infertility in adult female nonhuman primates. Fertil Steril 2011;95:1440-1445 e1441-1447.
169. Zhou J, Kumar TR, Matzuk MM, Bondy C. Insulin-like growth factor I regulates gonadotropin responsiveness in themurineovary. Mol Endocrinol 1997;11:1924-1933.
170. Zwain IH, Amato P. cAMP-induced apoptosis in granulosa cells is associated with up-regulation of P53 and bax and down-regulation of clusterin. Endocr Res 2001; 27:233-249.